Literature DB >> 18489525

Prognostic factors in a prospective series of papillary renal cell carcinoma.

Paolo Gontero1, Giovanni Ceratti, Sandro Guglielmetti, Antonella Andorno, Carlo Terrone, Daniele Bonvini, Fabrizio Faggiano, Alessandro Tizzani, Bruno Frea, Guido Valente.   

Abstract

OBJECTIVE: To prospectively assess the clinical outcome of a series of papillary renal cell carcinomas (PRCCs) to identify possible prognostic clinical variables and tumour markers, as previous retrospective series of PRCC do not provide unanimous results on the prognostic utility of clinicopathological variables. PATIENTS AND METHODS: Forty-six patients with PRCC (median follow-up 40 months) diagnosed in one institution from 1989 to 2002 were prospectively followed until May 2006. The pathology was reviewed, the PRCC subtyped (type 1 and 2) and immunohistochemistry assessed for MIB-1, vascular endothelial growth factor (VEGF), CD31 and c-met oncogenic protein, by a referee pathologist. Prognostic values were estimated by fitting a Cox model.
RESULTS: The 5-year survival rate was 49.5%; type 2 histology was predominant and was almost significant in the univariate analysis. Stage and MIB-1 were significant prognostic factors only in the univariate model, while the Cox model identified only the Fuhrman grade as an independent predictor of survival (hazard ratio 3.054; P = 0.007). MET expression, CD31 and VEGF had no prognostic utility.
CONCLUSION: These patients with PRCC followed prospectively fared worse than in previously reported series. The Fuhrman grade was the sole independent predictor of survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489525     DOI: 10.1111/j.1464-410X.2008.07756.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

Review 1.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

2.  Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.

Authors:  Andrew B Rosenkrantz; Aarti Sekhar; Elizabeth M Genega; Jonathan Melamed; James S Babb; Amish D Patel; Andy Lo; Robert M Najarian; Muneeb Ahmed; Ivan Pedrosa
Journal:  Eur Radiol       Date:  2012-08-21       Impact factor: 5.315

Review 3.  Sporadic bilateral synchronous multicentric papillary renal cell carcinoma masquerading as bilateral multifocal pyelonephritis.

Authors:  V S Karthikeyan; L N Dorairajan; S Kumar; A R Vijayakumar; A Ramesh; N Ganesh Rajesh; D Halanaik; S Gupta
Journal:  Ann R Coll Surg Engl       Date:  2014-07       Impact factor: 1.891

Review 4.  Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Authors:  Theodore F Logan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

5.  Microvessel density is high in clear-cell renal cell carcinomas of Ukrainian patients exposed to chronic persistent low-dose ionizing radiation after the Chernobyl accident.

Authors:  A M Romanenko; A Ruiz-Saurí; L Morell-Quadreny; G Valencia; A F Vozianov; A Llombart-Bosch
Journal:  Virchows Arch       Date:  2012-05-13       Impact factor: 4.064

Review 6.  MRI phenotype in renal cancer: is it clinically relevant?

Authors:  Naomi Campbell; Andrew B Rosenkrantz; Ivan Pedrosa
Journal:  Top Magn Reson Imaging       Date:  2014-04

7.  High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.

Authors:  Nu-Ri Jang; Jina Baek; Younghwii Ko; Phil Hyun Song; Mi-Jin Gu
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

8.  Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review.

Authors:  Jung Han Kim; Bum Jun Kim; Hyeong Su Kim
Journal:  Oncotarget       Date:  2017-09-08

Review 9.  Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Yongpeng Xie; Luyao Chen; Xin Ma; Hongzhao Li; Liangyou Gu; Yu Gao; Yang Fan; Yu Zhang; Xu Zhang
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

10.  Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals.

Authors:  Zhun Wang; Hui Xie; Linpei Guo; Qiliang Cai; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Cancer Manag Res       Date:  2017-11-21       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.